Clinical Trial Update: A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 study of once-daily oral Orforglipron (LY3502970) in Japanese adults with obesity. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity | Phase 3 | Status: COMPLETED